Affiliation:
1. Department of Pharmaceutical Microbiology and Bioanalysis, Medical University of Warsaw, Warsaw, Poland
2. Department of Antibiotics and Microbiology, National Medicines Institute, Warsaw, Poland
Abstract
The analysis of antimicrobial activity is usually MIC- and minimal bactericidal concentration (MBC)-focused, though also crucial are resistance-related parameters, e.g., the frequency of spontaneous mutant selection (FSMS), the mutant prevention concentration (MPC), and the mutant selection window (MSW).
In vitro
-determined MPCs, however, are sometimes variable, poorly repeatable, and not always reproducible
in vivo
. We propose a new approach to the
in vitro
determination of MSWs, along with novel parameters: MPC-D, MSW-D (for dominant mutants, i.e., selected with a high frequency, without a fitness loss), and MPC-F, MSW-F (for inferior mutants, i.e., with an impaired fitness).
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference61 articles.
1. WHO. 2022. 2021 Antibacterial agents in clinical and preclinical development: an overview and analysis. World Health Organization Geneva Switzerland. https://www.who.int/publications/i/item/9789240047655.
2. FDA. 2017. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases. FDA-2013-D-0744. US Food and Drug Administration Silver Spring MD.
3. The European Medicines Agency Approved the New Antibacterial Drugs – Response to the 2017 Who Report on the Global Problem of Multi-Drug Resistance
4. CLSI. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 9th ed. CLSI guideline M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
5. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. CLSI guideline M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.